QUIMATRYX
Reshaping the future of medicine through epigenetic innovation
Science. Precision. Impact
More than just a biotech company. We are a clinical-stage biotech company within the Oncomatryx Group, advancing next-generation epigenetic therapies.
We are a multidisciplinary team dedicated to pioneering precision medicine through epigenetic research, committed to improving patient lives across oncology, neurology, obesity, and autoimmune diseases.
We aspire to become a global leader in treating disease through the selective inhibition of HDAC6—an epiproteomic and epigenetic target implicated in numerous conditions.Unlocking the power of HDAC6 inhibitors
Founded in 2015 by Dr. Yosu Vara, Dr. Eneko Aldaba, and Dr. Laureano Simón, Quimatryx is focused on developing precision therapies trough epigenetic and epiproteomic innovation. Built on Oncomatryx’s management model and Ikerchem’s legacy (UPV/EHU spin-off), we’re advancing research in selective HDAC6 inhibitors to target diseases at their molecular core.
Our mission is to address unmet medical needs in oncology, neurodegeneration, and inflammation. We are developing highly selective HDAC6 inhibitors like QTX125 and QTX153, designed to treat cancers, including solid and hematologic tumors, as well as neurological disorders and obesity with limited treatment options.
By leveraging epigenetic mechanisms, we aim to create therapies that offer effective, targeted solutions with minimal risk to patient safety.
Our mission is to address unmet medical needs in oncology, neurodegeneration, and inflammation. We are developing highly selective HDAC6 inhibitors like QTX125 and QTX153, designed to treat cancers, including solid and hematologic tumors, as well as neurological disorders and obesity with limited treatment options.
By leveraging epigenetic mechanisms, we aim to create therapies that offer effective, targeted solutions with minimal risk to patient safety.
Our commitment to Precision Medicine
We are advancing the next frontier of medicine by leveraging the reversible mechanisms of epigenetics. Our HDAC6 inhibitors offer a new opportunity to intervene in diseases like cancer, neurodegenerative disorders, obesity, and autoimmune disorders, using precision therapies that target the root causes without disrupting normal cellular functions.
Together, we are committed to transforming patient care, delivering groundbreaking therapies that tackle the molecular pathways of disease at their source.
Together, we are committed to transforming patient care, delivering groundbreaking therapies that tackle the molecular pathways of disease at their source.
Our Pipeline: Pioneering Epigenetic Therapies
Our pipeline is focused on delivering transformative therapies for oncology, neurological disorders, and autoimmune diseases.
Key programs include QTX125, a highly selective HDAC6 inhibitor for cancer treatment, which has already received approval from China’s National Medical Products Administration (NMPA) to begin clinical trials, and QTX153, a non-hydroxmic HDAC6 inhibitor for neurological disorders, and obesity with robust preclinical results.
We are dedicated to translating the potential of epigenetics into treatments that change the course of disease.
We are dedicated to translating the potential of epigenetics into treatments that change the course of disease.
Clinical trials
If you are an investigator
Stay updated on our clinical trials. Our journey with QTX125 is just beginning, with the trial now underway.
If you are a patient
Clinical trials offer an opportunity to access cutting-edge therapies. Find out how joining a trial could make a difference in your treatment journey.
KEEP UP TO DATE WITH THE LATEST NEWS
